Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (April 2026)
29 slides from Cocrystal Pharma's investor presentation, April 2026
Slide 1: Potent antivirals to combat some of the most serious diseases facing humanity
Potent antivirals to combat some of the most serious diseases facing humanity Investor Presentation April 2026 Nasdaq: COCP www.cocrystalpharma.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our development pipeline; our technology platform’s ability to produce viable drug candidates at reduced development timelines and co
Slide 3: About Cocrystal Pharma
About Cocrystal Pharma Advancing programs in high-value antiviral drug targets • Norovirus • Influenza • Coronavirus and respiratory viruses Applying powerful, proprietary Drug candidates with clinically validated mechanisms of action drug discovery platform • Effectively cure viral diseases technol
Slide 4: Investment Highlights
Investment Highlights • Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases • Proprietary structure-based drug discovery platform technology provides opportunity for discovery and development of novel, broad-spectrum drug candidates • Advancing multip
Slide 5: Robust Pipeline Addressing Unmet Medical Needs
Robust Pipeline Addressing Unmet Medical Needs Multiple clinical assets poised to deliver significant growth 5 5
Slide 6: Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals
Proprietary Drug Discovery Platform Technology for Direct-Acting Antivirals Cocrystal’s technology platform provides potential for novel drug candidates at reduced development timelines and costs Grow drug target Select drug Hit-to-lead Lead X-ray crystals binding pocket process optimization Direct-
Slide 7: Unmet Need for Safe, Effective, Broad-Spectrum Therapies
Unmet Need for Safe, Effective, Broad-Spectrum Therapies • Urgent health risks with newly emerging viral outbreaks1,2 • Significant delay of effective new antiviral therapeutics and vaccine development • Challenging issues with current drug discovery approach – one-target/one-drug paradigm • Signifi
Slide 8: Norovirus and Coronavirus Program
Norovirus and Coronavirus Program Overview 8
Slide 9: Major Cause of Gastrointestinal Illness in Closed and Crowded Environments
Major Cause of Gastrointestinal Illness in Closed and Crowded Environments Cruise ships Restaurants Norovirus Nursing homes Military Schools Bronson Norwalk Elementary School 9
Slide 10: Norovirus Infection: No Approved Treatments or Vaccines Available
Norovirus Infection: No Approved Treatments or Vaccines Available • Highly contagious and rapidly spreading infection • Limited ability to curtail outbreaks • Infections can occur anywhere and any time of the year • Need for an effective, safe and easy-to-administer treatment and preventive that can
Slide 11: Cocrystal Viral Protease Inhibitors Block the Essential Replication Process
Cocrystal Viral Protease Inhibitors Block the Essential Replication Process Norovirus or SARS-CoV-2 Main (3CL) protease inhibitor 11 11
Slide 12: Big Surge of Norovirus Outbreaks in 2024-2025 After COVID-19 Pandemic
Big Surge of Norovirus Outbreaks in 2024-2025 After COVID-19 Pandemic 2024-2025 norovirus outbreaks 12 Reference: Science, 13 January 2025 12 Confidential
Slide 13: Protease Inhibitor CDI-988 for Norovirus and Coronavirus
Protease Inhibitor CDI-988 for Norovirus and Coronavirus (A) SARS-CoV-2 • Oral protease inhibitor targets noroviruses, coronaviruses and other 3CL viruses CDI-988 • Developed using Cocrystal’s proprietary drug discovery platform technology • Binds to a highly conserved region required for viral repl
Slide 14: Oral CDI-988 Showed Favorable Phase 1 Safety and Tolerability
Oral CDI-988 Showed Favorable Phase 1 Safety and Tolerability Phase 1 study design • Single-center, randomized, double-blind, placebo-controlled enrolling healthy volunteers (18-55 years old) • Each cohort comprised 8 participants (6 on CDI-988; 2 on placebo) 100 mg 200 mg 400 mg 400 mg 600 mg 100 m
Slide 15: CDI-988 Granted FDA Fast Track Designation for Norovirus Infection
CDI-988 Granted FDA Fast Track Designation for Norovirus Infection Treatment and Preventive • CDI-988 is the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection • Norovirus is a major unmet medical need with no approved treatments or vaccines • FDA Fas
Slide 16: CDI-988 Norovirus Challenge Phase 1b Study Underway
CDI-988 Norovirus Challenge Phase 1b Study Underway • First clinical trial involving a direct-acting antiviral specifically targeting norovirus infections • Study conducted in tightly controlled setting at Emory University School of Medicine • Challenge model to efficiently provide prophylaxis and t
Slide 17: Pandemic and Seasonal Influenza Program
Pandemic and Seasonal Influenza Program 17
Slide 18: Pandemic and Seasonal Influenza: A Major Global Health Concern
Pandemic and Seasonal Influenza: A Major Global Health Concern • 1 billion cases, 3-5 million severe illnesses and up to 650,000 deaths worldwide annually1 • Not well managed with currently approved vaccines having only 40-60% effectiveness2 • On average ~8% of the U.S. population contracts influenz
Slide 19: Influenza Development Programs Focused on Therapeutic Inhibitors
Influenza Development Programs Focused on Therapeutic Inhibitors Clinical assets for pandemic and seasonal influenza Promising Early-Stage Programs Oral PB2 inhibitor Replication inhibitors CC-42344 • Potent broad-spectrum activity against • Potent broad-spectrum activity against pandemic and season
Slide 20: CC-42344 Shows Broad-Spectrum Antiviral Activity Against Pandemic and Seasonal Influenza A Strains
CC-42344 Shows Broad-Spectrum Antiviral Activity Against Pandemic and Seasonal Influenza A Strains Influenza serotype Strain CC-42344, EC50 nM H1N1 A/PR/8/34 1 Pandemic H1N1 California/04/2009 0.5 H1N1 A1/Denver/1/57 3 H1N1 A/Fort Monmouth/1/47 2 H1N1 A/NY/18/09 5 H3N2 A/AICHI/2/68 0.2 Highly pathog
Slide 21: CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2 Protein
CC-42344 Binds to Highly Conserved Active Site of Influenza A PB2 Protein Cocrystal proprietary drug discovery platform technology Highly pathogenic influenza A strains H1N1 H5N1 H7N9 H432 H432 H432 F325 F325 N429 N429 F325 M431 M431 M431 CC-42344 CC-42344 CC-42344 F323 R355 R355 F323 F323 R35 H357
Slide 22: CC-42344 Demonstrates Strong Antiviral Potency Against 2024 Highly Pathogenic H5N1 Avian Flu Strain
CC-42344 Demonstrates Strong Antiviral Potency Against 2024 Highly Pathogenic H5N1 Avian Flu Strain U.S. Avian influenza A (H5N1) infection First cocrystal structure of 2024 Summary of Confirmed and Probable H5N1:CC-42344 Human Cases Since 2024 August 1, 2025 2024 HPAI:CC-42344 crystals Cocrystal in
Slide 23: CC-42344 Shows Potent Antiviral Activity in Influenza-Infected Human Lung Epithelium
CC-42344 Shows Potent Antiviral Activity in Influenza-Infected Human Lung Epithilium • Cells are killed by H1N1 virus, and Uninfected human bronchial most cilia are destroyed airway epithelia Influenza A H1N1 infection • Favorable safety profile: No toxicity in CC-42344- treated human lung No CC-423
Slide 24: Experienced Board of Directors
Experienced Board of Directors Roger Kornberg, Ph.D. • Nobel Laureate in Chemistry - the process by which genetic information from DNA is copied to RNA Co-founder, Chairman of the Board & • Welch Prize – highest award granted in the field of chemistry in the U.S. Chairman of the Scientific • Leopald
Slide 25: Seasoned Leadership
Seasoned Leadership Management Scientific Advisory Board Sam Lee, Ph.D. Roger Kornberg, Ph.D. • Professor Co-Chief Executive Officer & Chairman of the Board, Chairman of the Stanford University School of Medicine President Scientific Advisory Board • Nobel Laureate 25+ years of anti-infective drug d
Slide 26: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio Coronavirus Norovirus • Issued patents in U.S. and major countries • Issued patents in U.S. and major countries • Pending U.S. provisional applications • Pending U.S. provisional applications Pandemic Influenza A HCV • PB2 (influenza A inhibitor) NS5B (NNI)
Slide 27: Upcoming Clinical Milestones
Upcoming Clinical Milestones • CDI-988 as oral prophylaxis and treatment for norovirus infection ✓ Reported favorable Phase 1 results including high-dose cohort ✓ Dosing underway in Phase 1b challenge study • Phase 1b proof-of-concept data • CC-42344 as an oral treatment of pandemic and seasonal inf
Slide 28: Financial Snapshot
Financial Snapshot ~$20 Million 2.4 Million Average 3 month Market cap1 daily share volume1,2 $7.7 Million 11.3 Million 19.4 Million Cash/equivalents as of Common shares outstanding Fully diluted shares December 31, 2025 • No preferred shares and no debt 1 Yahoo Finance (April 7, 2026) 2 Includes 13
Slide 29: Investment Highlights
Investment Highlights • Targeting multibillion-dollar, global markets for the treatment of acute and pandemic viral diseases • Proprietary structure-based drug discovery platform technology provides opportunity for discovery and development of novel, broad-spectrum drug candidates • Advancing multip
Cocrystal Pharma — Investor Presentation (April 2026) on 6ix